Vertex Reaches Pricing Deal With NHS for Cystic Fibrosis Drugs
- Kaftrio, Symkevi and Orkambi are seen as life-changing
- The drugs were called too expensive last year by UK regulator
This article is for subscribers only.
Vertex Pharmaceuticals Inc. has reached a pricing deal for its cystic fibrosis drugs with the National Health Service in England, ending a yearslong campaign by patients to secure access to the medicines.
England’s drug pricing regulator, the National Institute for Health and Care Excellence (NICE), recommended the three drugs for patients with cystic fibrosis who have certain gene mutations in its final draft guidance Thursday.